FDA Accepts Cogent's NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Event summary
- FDA accepted Cogent's NDA for bezuclastinib in NonAdvSM with a PDUFA target date of December 30, 2026.
- SUMMIT trial data showed statistically significant improvements across primary and secondary endpoints.
- Bezuclastinib demonstrated favorable safety and tolerability for chronic use in NonAdvSM patients.
- NDA submissions for GIST and AdvSM indications remain on track for April 2026 and first half of 2026, respectively.
The big picture
Cogent's NDA acceptance for bezuclastinib marks a critical step in addressing NonAdvSM, a rare disease with high unmet medical need. The FDA's acceptance without review issues suggests a smooth regulatory path, while the upcoming submissions for GIST and AdvSM could expand the drug's market potential. The company's focus on precision therapies aligns with broader industry trends toward genetically targeted treatments.
What we're watching
- Regulatory Timelines
- Whether the FDA will meet the December 30, 2026 PDUFA target date for bezuclastinib approval.
- Clinical Efficacy
- How sustained clinical benefits observed in the SUMMIT trial will translate into long-term patient outcomes.
- Pipeline Progress
- The pace at which Cogent can advance its NDA submissions for GIST and AdvSM indications.
Related topics